NRX Pharmaceuticals (NRXP) Notes Payables (2019 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Notes Payables of $8.8 million for Q1 2026, down 11.02% year-over-year from $9.9 million in Q1 2025, and down 28.75% quarter-over-quarter from $12.3 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Notes Payables (2019 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Notes Payables for 7 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Notes Payables fell 11.02% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (down 11.02% YoY), while the FY2025 annual figure was $12.3 million, up 118.19% from the prior year.
- Notes Payables eased to $8.8 million in Q1 2026 per NRXP's latest filing, from $12.3 million in the prior quarter.
- Across five years, Notes Payables topped out at $12.3 million in Q4 2025 and bottomed at $17000.0 in Q4 2023.
- Historically, Notes Payables has averaged $5.1 million across 5 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2022 — Notes Payables sank 99.92% — and 2025, when it surged 37792.31%.
- NRX Pharmaceuticals' Notes Payables stood at $37000.0 in 2022, then sank by 54.05% to $17000.0 in 2023, then surged by 33070.59% to $5.6 million in 2024, then soared by 118.19% to $12.3 million in 2025, then declined by 28.75% to $8.8 million in 2026.
- Business Quant data shows NRXP's Notes Payables at $8.8 million in Q1 2026, $12.3 million in Q4 2025, and $9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - |
| 10 | NRX Pharmaceuticals | 133.09 Mn | 106.39 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.77 Mn |
| Dec 31, 2025 | 12.30 Mn |
| Sep 30, 2025 | 9.91 Mn |
| Jun 30, 2025 | 9.85 Mn |
| Mar 31, 2025 | 9.85 Mn |
| Dec 31, 2024 | 5.64 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 10.07 Mn |
| Jun 30, 2023 | 36,000.00 |
| Mar 31, 2023 | 12.19 Mn |
| Dec 31, 2022 | 37,000.00 |
| Sep 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 19,000.00 |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 292,000.00 |
| Sep 30, 2021 | 1.26 Mn |
| Jun 30, 2021 | 22.85 Mn |
| Mar 31, 2021 | 1.97 Mn |